Benitec Biopharma Inc. (BNTC)
NCM · Healthcare · Biotechnology
Closing price as of 2026-10-28 · Source: TEK2day Finance
Key Metrics
About Benitec Biopharma Inc.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | ||||
| Operating Income | (9.8M) | (13.4M) | (13.6M) | (14.4M) |
| Net Income | (9.0M) | (11.8M) | (11.9M) | (12.8M) |
| Diluted EPS | $-0.22 | $-0.26 | $-0.24 | N/A |
Annual Financials
| Metric | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 75K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 75K | |||
| Operating Income | (19.1M) | (22.5M) | (41.8M) | (51.2M) |
| Net Income | (19.6M) | (21.8M) | (37.9M) | (45.5M) |
| Diluted EPS | $-14.12 | $-1.22 | $-1.05 | $-0.98 |